Biological treatment is approved for severe eosinophilic asthmaBMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i6472 (Published 01 December 2016) Cite this as: BMJ 2016;355:i6472
- Susan Mayor
Draft guidance from the National Institute for Health and Care Excellence (NICE) recommends the monoclonal antibody mepolizumab as an option to treat adult patients with severe refractory asthma and raised eosinophil levels.1
The decision follows an agreement by the manufacturer, GlaxoSmithKline (GSK), to reduce the price of the drug—which has a list price of £840 (€992; $1046) for a once monthly dose—to a lower, but undisclosed, cost to the NHS.
Mepolizumab is a humanised monoclonal antibody that binds to interleukin …
Log in using your username and password
Log in through your institution
Sign up for a free trial